Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region

Table 1 Patients’ clinical characteristics

Sample		85
Age		6-88	Median: 60
Gender	Female	36
	Male	49
Removal	Biopsy	1
	Partial	29
	Subtotal	28
	Total	20
	Unknown	8
Post operative therapy	VAC-feron	57
	Temozolomide	14
	Other ACNU regimen	4
	Radiation alone	7
	Other	3
Overall survival (months)		3-96	Median: 12
Progression free survival (months)		1-96	Median: 6

ISSN: 1471-2407